Guidelines recommend low‐molecular‐weight heparins (LMWHs) for patients with cancer‐associated thrombosis. However, until recently, only dalteparin and tinzaparin were approved in the European Economic Area (EEA) for these patients. This study… Click to show full abstract
Guidelines recommend low‐molecular‐weight heparins (LMWHs) for patients with cancer‐associated thrombosis. However, until recently, only dalteparin and tinzaparin were approved in the European Economic Area (EEA) for these patients. This study compares the benefit–risk profile of enoxaparin with dalteparin and tinzaparin for the extended treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrence in adult patients with active cancer.
Keywords:
cancer;
benefit risk;
deep vein;
treatment deep;
extended treatment;
thrombosis
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!